NASDAQ:NEUP

Neuphoria Therapeutics Q1 2026 Earnings Results & Report

Neuphoria Therapeutics logo
$2.29 +0.02 (+0.88%)
Closing price 03:59 PM Eastern
Extended Trading
$2.28 -0.01 (-0.44%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neuphoria Therapeutics missed analyst earnings expectations in its Q1 2026 results, released November 14, 2025. The company reported EPS of -$4.41 versus the -$0.55 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Neuphoria Therapeutics EPS Results

Actual EPS
-$4.41
Consensus EPS
-$0.55
Beat/Miss
Missed by -$3.86
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 6 quarters

Neuphoria Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Neuphoria Therapeutics Q1 2026 Earnings FAQ

Neuphoria Therapeutics (NASDAQ:NEUP) reported earnings of -$4.41 per share for Q1 2026, missing the consensus estimate of -$0.55. The report was announced on Friday, November 14, 2025.

Neuphoria Therapeutics Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Neuphoria Therapeutics Inc Ordinary Shares NEUP
Neuphoria Therapeutics Inc (NEUP)
See More Neuphoria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email.

About Neuphoria Therapeutics

Neuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions.

The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies.

Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

View Neuphoria Therapeutics Profile